Fig. 5.

a Schematic illustration of the construction of CuS–BSA–FA as a vehicle to deliver ICG showing the mechanism of PDT and PTT therapies. b Cytotoxicity assays on HeLa cells in the presence of CuS–BSA–FA, ICG and CuS–BSA–FA/ICG with or without NIR irradiation (1 W cm⁻² for 5 min). c HeLa cells in the presence of CuS–BSA–FA (60 mg mL⁻¹), ICG (2 mg mL⁻¹) and CuS–BSA–FA/ICG (60 mg mL⁻¹ for CuS–BSA–FA and 2 mg mL⁻¹ for ICG) with and without laser irradiation (1 W cm⁻²). Reproduced with permission from Ref.[51]. Copyright 2016, Royal Society of Chemistry, Washington, DC